Last reviewed · How we verify
Magnesium sulfate 12 hours
Magnesium sulfate acts as a central nervous system depressant and anticonvulsant by blocking N-methyl-D-aspartate (NMDA) receptors and reducing neuromuscular transmission.
Magnesium sulfate acts as a central nervous system depressant and smooth muscle relaxant by blocking neuromuscular transmission and reducing acetylcholine release. Used for Seizure prophylaxis and treatment in preeclampsia and eclampsia, Acute seizure management in pregnancy, Hypomagnesemia.
At a glance
| Generic name | Magnesium sulfate 12 hours |
|---|---|
| Sponsor | Instituto Materno Infantil Prof. Fernando Figueira |
| Drug class | Anticonvulsant, electrolyte supplement |
| Target | Neuromuscular junction (calcium channel antagonist at motor endplate) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics, Neurology |
| Phase | FDA-approved |
Mechanism of action
Magnesium sulfate works through multiple mechanisms: it blocks NMDA receptors to reduce neuronal excitability, acts as a natural calcium antagonist to inhibit acetylcholine release at the neuromuscular junction, and stabilizes cell membranes. The 12-hour dosing regimen suggests use in obstetrics for seizure prophylaxis in preeclampsia/eclampsia, where sustained magnesium levels are maintained to prevent convulsions.
Approved indications
- Seizure prophylaxis in preeclampsia and eclampsia
- Hypomagnesemia treatment
- Tocolysis in preterm labor
Common side effects
- Flushing
- Sweating
- Hyporeflexia
- Muscle weakness
- Respiratory depression
- Hypotension
Key clinical trials
- Biomarkers in Management of Post Partum Preeclampsia (PHASE4)
- The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- The Efface of Ketamine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial (PHASE4)
- Abbreviated MgSO4 Therapy in Post-partum Preeclampsia (NA)
- TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden (PHASE3)
- A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy (PHASE4)
- Patient Satisfaction With Abbreviated Postpartum Magnesium Sulfate for Severe Preeclampsia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: